On May 20, WuXi XDC rose 3.17% in regular trading, trading at 56.65 HKD/share, with trading volume of approximately 55.86 million HKD. The gain follows the company's announcement of a significant share repurchase program.

On May 18, WuXi XDC announced that it has resolved to deploy up to $100 million in internal funds, appointing a professional trustee to purchase company shares on the open market at prevailing prices. The board explicitly stated that the current share price does not reflect the company's intrinsic value or actual business prospects, viewing this as an opportune time for buybacks. The board further noted that the group's financial resources are sufficient to implement the repurchase while maintaining a solid financial position for continued operational growth.

Additionally, JPMorgan recently reiterated its positive outlook on WuXi XDC, naming it a top sector pick, citing accelerating commercialization of innovative drugs in China that would directly benefit CRDMO partners. The broader biopharma sector has shown strength recently, compounding the buyback tailwind and supporting the stock's upward momentum for a second consecutive session.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)